Skip to main content

ACUMULO DE PROTEINA PRECURSORA DE AMILOIDE-C99 (APP-C99) COMO MECANISMO DE ENFERMEDAD EN LA ENFERMEDAD DE ALZHEIMER: IMPLICACIONES TERAPEUTICAS.

PI20/01330

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO
Execution centre IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 20
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology

  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Scheeren Brum, Wagner|||0000-0002-9777-0559
  • Molfetta, Guglielmo Di
  • Benedet, Andréa Lessa
  • Arslan, Burak
  • Jonaitis, Erin Mc Mullen
  • Langhough, Rebecca E.
  • Cody, Karly Alex
  • Wilson, Rachael E.
  • Carlsson, Cynthia M.
  • Vanmechelen, Eugeen|||0000-0002-9466-5366
  • Montoliu Gaya, Laia|||0000-0001-7684-6318
  • Lantero Rodríguez, Juan|||0000-0002-7426-678X
  • Rahmouni, Nesrine
  • Tissot, Cécile
  • Stevenson, Jenna
  • Servaes, Stijn|||0000-0002-4431-957X
  • Therriault, Joseph
  • Pascoal, Tharick|||0000-0001-9057-8014
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Rosa-Neto, Pedro|||0000-0001-9116-1376
  • Johnson, Sterling C.
  • Jeromin, Andreas
  • Blennow, Kaj|||0000-0002-1890-4193
  • Zetterberg, Henrik|||0000-0003-3930-4354
IMPORTANCE Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease (AD) pathology, with p-tau217 considered to have the most utility. However, availability of p-tau217 tests for research and clinical use has been limited. Expanding access to this highly accurate AD biomarker is crucial for wider evaluation and implementation of AD blood tests. OBJECTIVE To determine the utility of a novel and commercially available immunoassay for plasma p-tau217 to detect AD pathology and evaluate reference ranges for abnormal amyloid β (Aβ) and longitudinal change across 3 selected cohorts. DESIGN, SETTING, AND PARTICIPANTS This cohort study examined data from 3 single-center observational cohorts: cross-sectional and longitudinal data from the Translational Biomarkers in Aging and Dementia (TRIAD) cohort (visits October 2017-August 2021) and Wisconsin Registry for Alzheimer's Prevention (WRAP) cohort (visits February 2007-November 2020) and cross-sectional data from the Sant Pau Initiative on Neurodegeneration (SPIN) cohort (baseline visits March 2009-November 2021). Participants included individuals with and without cognitive impairment grouped by amyloid and tau (AT) status using PET or CSF biomarkers. Data were analyzed from February to June 2023. EXPOSURES Magnetic resonance imaging, Aβ positron emission tomography (PET), tau PET, cerebrospinal fluid (CSF) biomarkers (Aβ42/40 and p-tau immunoassays), and plasma p-tau217 (ALZpath pTau217 assay). MAIN OUTCOMES AND MEASURES Accuracy of plasma p-tau217 in detecting abnormal amyloid and tau pathology, longitudinal p-tau217 change according to baseline pathology status. RESULTS The study included 786 participants (mean [SD] age, 66.3 [9.7] years; 504 females [64.1%] and 282 males [35.9%]). High accuracy was observed in identifying elevated Aβ (area under the curve [AUC], 0.92-0.96; 95% CI, 0.89-0.99) and tau pathology (AUC, 0.93-0.97; 95% CI, 0.84-0.99) across all cohorts. These accuracies were comparable with CSF biomarkers in determining abnormal PET signal. The detection of abnormal Aβ pathology using a 3-range reference yielded reproducible results and reduced confirmatory testing by approximately 80%. Longitudinally, plasma p-tau217 values showed an annual increase only in Aβ-positive individuals, with the highest increase observed in those with tau positivity. CONCLUSIONS AND RELEVANCE This study found that a commercially available plasma p-tau217 immunoassay accurately identified biological AD, comparable with results using CSF biomarkers, with reproducible cut-offs across cohorts. It detected longitudinal changes, including at the preclinical stage.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cortical microinfarcts in adults with Down syndrome assessed with 3T-MRI

  • Aranha, Mateus|||0000-0001-9594-292X
  • Montal, Victor|||0000-0002-5714-9282
  • van den Brink, Hilde
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Benejam, Bessy|||0000-0002-6789-8615
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Fernández, Susana|||0000-0002-9777-1156
  • Ribas, Laia
  • Alcolea, Daniel|||0000-0002-3819-3245
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Bargalló, Núria|||0000-0001-6284-5402
  • Biessels, Geert Jan|||0000-0001-6862-2496
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Coutinho, Artur Martins|||0000-0002-5555-4583
  • Leite, Cláudia Costa
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Fortea, Juan|||0000-0002-1340-638X
Cortical microinfarcts (CMI) were attributed to cerebrovascular disease and cerebral amyloid angiopathy (CAA). CAA is frequent in Down syndrome (DS) while hypertension is rare, yet no studies have assessed CMI in DS. We included 195 adults with DS, 63 with symptomatic sporadic Alzheimer's disease (AD), and 106 controls with 3T magnetic resonance imaging. We assessed CMI prevalence in each group and CMI association with age, AD clinical continuum, vascular risk factors, vascular neuroimaging findings, amyloid/tau/neurodegeneration biomarkers, and cognition in DS. CMI prevalence was 11.8% in DS, 4.7% in controls, and 17.5% in sporadic AD. In DS, CMI increased in prevalence with age and the AD clinical continuum, was clustered in the parietal lobes, and was associated with lacunes and cortico-subcortical infarcts, but not hemorrhagic lesions. In DS, CMI are posteriorly distributed and related to ischemic but not hemorrhagic findings suggesting they might be associated with a specific ischemic CAA phenotype. This is the first study to assess cortical microinfarcts (assessed with 3T magnetic resonance imaging) in adults with Down syndrome (DS). We studied the prevalence of cortical microinfarcts in DS and its relationship with age, the Alzheimer's disease (AD) clinical continuum, vascular risk factors, vascular neuroimaging findings, amyloid/tau/neurodegeneration biomarkers, and cognition. The prevalence of cortical microinfarcts was 11.8% in DS and increased with age and along the AD clinical continuum. Cortical microinfarcts were clustered in the parietal lobes, and were associated with lacunes and cortico-subcortical infarcts, but not hemorrhagic lesions. In DS, cortical microinfarcts are posteriorly distributed and related to ischemic but not hemorrhagic findings suggesting they might be associated with a specific ischemic phenotype of cerebral amyloid angiopathy.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Characterization of white matter hyperintensities in Down syndrome

  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Zsadanyi, Sara E.|||0000-0002-2033-5989
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Montal, Victor|||0000-0002-5714-9282
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Aranha, Mateus|||0000-0001-9594-292X
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Padilla, Concepción|||0000-0003-4102-6787
  • Benejam, Bessy|||0000-0002-6789-8615
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Fernandez, S.
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Giménez, Sandra|||0000-0001-8031-2319
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Bargalló, Núria|||0000-0001-6284-5402
  • Ribas, Laia
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Torres Alcalá, Soraya|||0000-0002-7054-2046
  • Iulita, M. Florencia|||0000-0002-3360-4498
  • Belbin, Olivia|||0000-0002-6109-6371
  • Camacho, Valle|||0000-0003-0748-0847
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Bejanin, Alexandre|||0000-0002-9958-0951
INTRODUCTION: In Down syndrome (DS), white matter hyperintensities (WMHs) are highly prevalent, yet their topography and association with sociodemographic data and Alzheimer's disease (AD) biomarkers remain largely unexplored. METHODS: In 261 DS adults and 131 euploid controls, fluid-attenuated inversion recovery magnetic resonance imaging scans were segmented and WMHs were extracted in concentric white matter layers and lobar regions. We tested associations with AD clinical stages, sociodemographic data, cerebrospinal fluid (CSF) AD biomarkers, and gray matter (GM) volume. RESULTS: In DS, total WMHs arose at age 43 and showed stronger associations with age than in controls. WMH volume increased along the AD continuum, particularly in periventricular regions, and frontal, parietal, and occipital lobes. Associations were found with CSF biomarkers and temporo-parietal GM volumes. DISCUSSION: WMHs increase 10 years before AD symptom onset in DS and are closely linked with AD biomarkers and neurodegeneration. This suggests a direct connection to AD pathophysiology, independent of vascular risks. Highlights: White matter hyperintensities (WMHs) increased 10 years before Alzheimer's disease symptom onset in Down syndrome (DS). WMHs were strongly associated in DS with the neurofilament light chain biomarker. WMHs were more associated in DS with gray matter volume in parieto-temporal areas.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Alpha-synuclein co-pathology in Down syndrome-associated Alzheimer's disease

  • Bernhardt, Alexander Maximilian
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Aldecoa, Iban|||0000-0001-5774-7453
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Longen, Sebastian
  • Trossbach, Svenja Verena
  • Giese, Armin
  • Matthias, Torsten
  • Benejam, Bessy|||0000-0002-6789-8615
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Sanjuan, Aída
  • Fernández, Susana|||0000-0002-9777-1156
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Aranha, Mateus|||0000-0001-9594-292X
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Nübling, Georg|||0000-0003-4492-7302
  • Wagemann, Olivia
  • Stockbauer, Anna
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Molina-Porcel, Laura|||0000-0003-4068-8578
  • Fortea, Juan|||0000-0002-1340-638X
  • Levin, Johannes|||0000-0001-5092-4306
Alpha-synuclein (αSyn) seed amplification assay (SAA) enables in vivo study of αSyn but remains underexplored in Down syndrome-associated Alzheimer's disease (DSAD). We analyzed αSyn-SAA in cerebrospinal fluid (CSF) from 270 adults with Down syndrome, from the Down Alzheimer Barcelona Neuroimaging Initiative and from the AD21 cohort from the Department of Neurology at the University Hospital, Ludwig Maximilian University of Munich, Germany. Neuropathological examinations were conducted in 19 brain donors (five with ante mortem CSF). Participants were classified as asymptomatic or symptomatic (prodromal/dementia) Alzheimer's disease (AD). CSF Aβ1-42/1-40, CSF and plasma p-Tau181, and neurofilament light chain (NfL) levels were measured. Neuropathological evaluations assessed AD neuropathological changes and Lewy body pathology (LBP). ΑSyn-SAA was positive in 9.2% of cases, independent of age or cognitive status. Symptomatic αSyn-positive cases exhibited higher plasma NfL levels than αSyn-negative cases (31 vs 21 pg/mL, p = 0.027). LBP was observed in 47% of necropsies. The individual with severe neocortical LBP was αSyn-SAA-positive. These findings highlight LBP prevalence in DSAD but suggest current SAA may fail to detect limited αSyn deposition.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Generational effects in Down syndrome, Enriched environment enhances functionality without reducing Alzheimer's disease risk

  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Benejam, Bessy|||0000-0002-6789-8615
  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Fernández, Susana|||0000-0002-9777-1156
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Sanjuan, Aída
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Arenaza-Urquijo, Eider|||0000-0001-7016-7576
  • Lleó, Alberto|||0000-0002-2568-5478
  • Bartrés-Faz, David|||0000-0001-6020-4118
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Fortea, Juan|||0000-0002-1340-638X
Down syndrome (DS) is the leading cause of intellectual disability (ID) and a genetic form of Alzheimer's disease (AD). We wanted to assess whether generational changes have induced (1) milder ID with greater independence and (2) delayed AD diagnosis. We analyzed 681 asymptomatic DS to test generational effects on ID, functionality, and cognition. In 353 DS individuals with AD, we compared clinical diagnosis age by ID using analysis of variance. In addition, dementia diagnosis age was examined through a published meta-analysis. Our results indicate a generational shift toward a higher proportion of individuals with mild/moderate ID, greater intelligence, and autonomy. However, it was not paralleled by an ID-related delay in the age at AD onset in our cohort, or by generational delays reported over the past 35 years. The findings highlight notable generational improvements in DS, but no effects on the age at AD dementia diagnosis. OrderedDict([(u'list', OrderedDict([(u'@list-type', u'bullet'), (u'@id', u'alz70447-list-0001'), (u'list-item', [OrderedDict([(u'p', u'A generational effect has reduced the severity of intellectual disability in Down syndrome (DS).')]), OrderedDict([(u'p', u'Individuals with DS have increased autonomy and improved intellectual milestones.')]), OrderedDict([(u'p', u"The enriched environment has not delayed the age at Alzheimer's disease (AD) dementia in DS.")]), OrderedDict([(u'p', u'Further studies should confirm if cognitive reserve might delay AD in DS.'.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Nerve growth factor precursor alterations in neuron-derived extracellular vesicles from individuals with Down syndrome along the Alzheimer's disease continuum

  • Valle-Tamayo, Natalia|||0000-0001-9322-3710
  • Aranha, Mateus|||0000-0001-9594-292X
  • Pérez-González, R.
  • Serrano-Requena, S.
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Benejam, Bessy|||0000-0002-6789-8615
  • Chiva-Blanch, Gemma|||0000-0001-6093-0160
  • Jiménez Pineda, Amanda|||0000-0003-4967-1174
  • Busciglio, J.
  • Wisniewski, Thomas M.
  • Carmo, S.D.
  • Álvarez-Sánchez, Esther|||0009-0002-8760-2153
  • Muñoz, L.
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Belbin, Olivia|||0000-0002-6109-6371
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Lleó, Alberto|||0000-0002-2568-5478
  • Cuello, AC.|||0000-0003-2143-2745
  • Fortea, Juan|||0000-0002-1340-638X
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Iulita, M. Florencia|||0000-0002-3360-4498
BACKGROUND: In Down syndrome (DS) and Alzheimer's disease (AD), nerve growth factor precursor protein (proNGF) accumulates in the brain. However, its non-invasive detection using neuron-derived extracellular vesicles (NDEVs) from plasma remains unexplored. METHODS: We included 139 adults with DS (45 asymptomatic [aDS], 94 symptomatic for AD [sDS]) and 37 healthy controls. NDEVs were isolated from plasma. ProNGF and tetraspanin (CD81) were quantified by enzyme-linked immunosorbent assay. We assessed proNGF/CD81 changes with age, along the AD continuum (aDS and sDS), and associations with cerebrospinal fluid (CSF), plasma biomarkers, episodic memory, and basal forebrain volume. RESULTS: In DS, proNGF/CD81 levels increased with age and were higher in NDEVs from asymptomatic and symptomatic individuals compared to controls, with the highest levels in the symptomatic group. ProNGF correlated with CSF phosphorylated tau (p-tau)181, plasma p-tau217, neurofilament light chain, and episodic memory. DISCUSSION: ProNGF/CD81 levels in NDEVs increase along the AD continuum in DS and parallel tau pathology, indicating the potential as a promising biomarker for monitoring disease progression in plasma. Highlights: Nerve growth factor precursor protein (ProNGF)/tetraspanin (CD81) ratio increased in the third decade of life, 20 years before Alzheimer's disease (AD) symptom onset in Down syndrome (DS). proNGF/CD81 concentrations were significantly higher in individuals with DS compared to controls and were notably elevated in individuals with DS and symptomatic AD compared to asymptomatic AD. proNGF/CD81 concentrations were associated with tau pathology and neuronal injury.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Sex differences in the executive and behavioral reserve of autosomal dominant frontotemporal dementia

  • Garcia Castro, Jesús|||0000-0003-1503-4775
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Casaletto, Kaitlin B.
  • Selma Gonzalez, Judit|||0009-0006-1021-4653
  • Memel, M.|||0000-0001-6827-6335
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Belbin, Olivia|||0000-0002-6109-6371
  • Fortea, Juan|||0000-0002-1340-638X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Heuer, H.W.
  • Forsberg, L.K.
  • Kantarci, K.
  • Staffaroni, Adam M.
  • Tartaglia, C.
  • Rankin, K.P.
  • Boeve, Bradley
  • Boxer, A.
  • Rosen, H.J.
  • Lleó, Alberto|||0000-0002-2568-5478
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
INTRODUCTION: Self-reported sex influences brain resilience, but its role in genetic frontotemporal dementia (FTD) remains unclear. METHODS: We analyzed 394 genetic-FTD patients and 279 controls from the ALLFTD consortium, assessing annual neuropsychological performance and MRI-based cortical thickness. Clinical characteristics and cortical thickness were compared between sexes. We used the residuals of linear regression models, which predict each participant's cognitive and behavioral performance levels relative to cortical thickness, as a proxy for reserve. We then modeled sex differences in longitudinal trajectories with linear mixed-effects models. RESULTS: Symptomatic females with genetic FTD had lower frontal cortical thickness than males, and the C9orf72 subgroup showed lower-than-expected frontal cortical thickness for a given level of executive functioning. Differences in cognitive reserve between sexes peaked near symptom onset but diminished thereafter. DISCUSSION: Females with genetic FTD showed higher cognitive reserve than males, suggesting that self-reported sex modulates resilience to frontotemporal neurodegeneration. Highlights: Females with genetic FTD showed higher cognitive reserve than males. Those differences were particularly pronounced in the C9orf72 and GRN subgroups. The higher cognitive reserve in females declined as the disease progressed.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Impact of Alzheimer's disease on sleep in adults with Down syndrome

  • Giménez, Sandra|||0000-0001-8031-2319
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Zhu, Nuole|||0000-0002-0015-9455
  • Benejam, Bessy|||0000-0002-6789-8615
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Rebillat, Anne-Sophie|||0000-0003-1995-9177
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Bueno-López, Ana|||0000-0003-2390-219X
  • Fernández, Susana|||0000-0002-9777-1156
  • Ribas, Laia
  • Zsadanyi, Sara E.|||0000-0002-2033-5989
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Lisgaras, Christos Panagiotis
  • Blessing, Esther
  • Osorio, Ricardo S.
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
INTRODUCTION: Down syndrome (DS) is a genetic form of Alzheimer's disease (AD), with a high prevalence of sleep disorders, but data in adults with DS and dementia are lacking. We aim to assess sleep in adults with DS across the AD continuum. METHODS: We studied 78 healthy controls and 229 adults with DS (154 asymptomatic, 25 with prodromal AD, and 75 with AD) with subjective sleep measures and objective nocturnal polysomnography. RESULTS: Adults with DS presented worse sleep quality and higher prevalence of unnoticed obstructive sleep apnea (OSA) than controls. Sleep disruption and OSA severity increased across the AD continuum. Age-related decreases in slow-wave sleep and rapid eye movement sleep were more pronounced in the DS group. Subjective sleep measures did not capture sleep disorders. CONCLUSIONS: In DS, AD is linked to worse sleep disturbances and altered architecture. However, longitudinal studies are needed to clarify directionality and disease progression. Highlights: Down syndrome (DS) is associated with increased slow-wave sleep (SWS) and reduced rapid eye movement (REM) sleep. Obstructive sleep apnea prevalence increases along the Alzheimer's disease continuum in DS. Age-related decreases in SWS and REM sleep are accelerated in DS. Subjective sleep measures do not detect sleep disturbances in adults with DS.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) and its contributions to understanding Alzheimer's disease in Down syndrome, A decade of discovery

  • Videla Toro, Laura|||0000-0002-9748-8465
  • Benejam, Bessy|||0000-0002-6789-8615
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Fernández, Susana|||0000-0002-9777-1156
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Estellés, Teresa
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Aranha, Mateus|||0000-0001-9594-292X
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Padilla, Concepción|||0000-0003-4102-6787
  • Valle-Tamayo, Natalia|||0000-0001-9322-3710
  • Sánchez-Aced, Érika|||0000-0001-7280-7493
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Sirisi Dolcet, Sonia|||0000-0002-5366-7832
  • Muñoz, Laia|||0000-0003-0578-3094
  • Torres Alcalá, Soraya|||0000-0002-7054-2046
  • Sánchez López, Oriol|||0000-0001-9405-1236
  • Garzón, Diana
  • Ribas, Laia
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Camacho, Valle|||0000-0003-0748-0847
  • Giménez, Sandra|||0000-0001-8031-2319
  • Delaby, Constance|||0000-0002-8606-6814
  • Belbin, Olivia|||0000-0002-6109-6371
  • Montal, Victor|||0000-0002-5714-9282
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Clarimón, Jordi|||0000-0002-6824-6942
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Molina-Porcel, Laura|||0000-0003-4068-8578
  • Aldecoa, Iban|||0000-0001-5774-7453
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Videla, Sebastià
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Fortea, Juan|||0000-0002-1340-638X
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Sanjuan, Aída
  • Zsadanyi, Sara E.|||0000-0002-2033-5989
  • Franquesa-Mullerat, Maria|||0009-0006-1484-7132
  • Carreras, Mireia
  • Lorente, Oriol
  • Bounasr El Bennadi, Shaima El
  • Elbachiri, Sumia
  • Mota, Cecilia
  • Iulita, M. Florencia|||0000-0002-3360-4498
Down syndrome (DS) is a genetic form of Alzheimer's disease (AD) that offers crucial insights into AD pathogenesis. The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) is a population-based multimodal biomarker cohort studying AD's natural history and clinical trials in DS. DABNI included 1135 participants (mean age 42.82, 46.3% female). At baseline, 673 participants were cognitively stable, 113 had prodromal AD, 239 had AD dementia, and 110 were uncertain due to non-AD conditions. Over 10 years, > 10000 clinical visits were conducted; follow-up showed that progression to symptomatic AD before age 40 was rare, but rates increased after age 50 (> 50% within 5 years). Neuropsychological and biomarker assessments demonstrated excellent diagnostic performance and a predictable sequence of changes, similar to autosomal dominant AD. DABNI participates in AD clinical trials and produced approximately 100 publications. The 10-year DABNI study provided critical insights into DS-associated AD (DSAD) and serves as a key platform for DS clinical trials. Highlights: Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) is a population-based multimodal cohort studying Alzheimer's disease in Down syndrome. Over 10 years, 1135 participants contributed to more than 10000 clinical visits and extensive biomarker studies. DABNI findings have transformed the understanding of Alzheimer's disease in Down syndrome, reinforcing its classification as a genetic form of the disease. The cohort integrates clinical care and research, enhancing early detection and patient management. DABNI supports clinical trials and has produced over 100 publications advancing Down syndrome-related Alzheimer's research.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Study of brain perfusion in adults with Down Syndrome along the Alzheimer's Disease continuum

  • Franquesa-Mullerat, Maria|||0009-0006-1484-7132
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Zsadanyi, Sara E.|||0000-0002-2033-5989
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Aranha, Mateus|||0000-0001-9594-292X
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Benejam, Bessy|||0000-0002-6789-8615
  • Fernández, Susana|||0000-0002-9777-1156
  • Hernandez, Aida Sanjuan
  • Giménez, Sandra|||0000-0001-8031-2319
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Lleó, Alberto|||0000-0002-2568-5478
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Fortea, Juan|||0000-0002-1340-638X
  • Bejanin, Alexandre|||0000-0002-9958-0951
Down Syndrome (DS) represents a high-risk group for Alzheimer's disease (AD) due to chromosome 21 triplication, which drives amyloid precursor protein overproduction. While brain atrophy in DS has been widely studied, the underlying brain perfusion changes remain poorly understood. This study leverages MRI pseudo-continuous arterial spin labeling (pCASL) to explore early cerebral blood flow (CBF) alterations along the AD continuum in DS and compares these changes to the perfusion patterns seen in sporadic AD (sAD) We performed a cross-sectional analysis including 32 euploid cognitively unimpaired individuals (eCU, age= 56.8yo, 68.7% female), 37 adults with DS (age= 42.64y; females= 37.83%, 40.5% symptomatic including n = 8 prodromal AD and n = 7 dementia) and 24 sAD patients (age 74.2yo, 50% female, 16 MCI and 8 in dementia stage) from the SPIN and DABNI cohorts that underwent 3T-MRI. pCASL images were preprocessed using ASLprep. Analyses explored the effects of demographic variables (age, sex), clinical stages, and AD biomarkers (including cerebrospinal fluid [CSF] Aβ1-42/Aβ1-40 ratio, pTau-181, and hippocampal volume) on global and regional CBF. Age-related decreases in cerebral blood flow (CBF) were observed in prefrontal regions in eCU, parietal structures in DS, and temporal lobes in sAD (Figure 1 A-D). Females had higher perfusion than males in eCU and sAD, but not in DS (Figure 1 E-H). In DS, CBF was reduced in temporal-parietal regions in asymptomatic individuals, extending to frontal areas in symptomatic cases, resembling sAD patterns (Figure 2). Symptomatic DS showed significantly lower CBF in lateral parietal regions than asymptomatic DS. Temporoparietal CBF correlated negatively with CSF-pTau-181 and positively with CSF-Aβ1-42/Aβ1-40 ratio and hippocampal volume, with the strongest association seen with hippocampal volume (Figure 3) Brain perfusion is significantly altered in adults with DS along the AD continuum, with changes detectable even before clinical symptoms. Hypoperfusion primarily affects temporoparietal and frontal regions at the symptomatic stage, closely resembling patterns seen in sAD. Notably, perfusion in the parietal areas differentiates asymptomatic from symptomatic DS and correlates strongly with key AD biomarkers. These findings highlight the potential of pCASL to detect early functional changes in this high-risk population.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Association of blood-based DNA methylation markers with late-onset alzheimer disease: a potential diagnostic approach

  • Acha Santamaría, Blanca
  • Corroza, Jon
  • Sánchez Ruiz de Gordoa, Javier
  • Cabello, Carolina
  • Robles Solano, Maitane
  • Méndez López, Iván
  • Macías, Mónica
  • Zueco, Sara
  • Roldán, Miren
  • Urdánoz Casado, Amaya
  • Jericó Pascual, Ivonne
  • Erro Aguirre, María Elena
  • Alcolea, Daniel
  • Lleo, Alberto
  • Blanco Luquin, Idoia
  • Mendióroz Iriarte, Maite
Background and Objectives: There is an urgent need to identify novel noninvasive biomarkers for Alzheimer disease (AD) diagnosis. Recent advances in blood-based measurements of phosphorylated tau (pTau) species are promising but still insufficient to address clinical needs. Epigenetics has been shown to be helpful to better understand AD pathogenesis. Epigenetic biomarkers have been successfully implemented in other medical disciplines, such as oncology. The objective of this study was to explore the diagnostic accuracy of a blood-based DNA methylation marker panel as a noninvasive tool to identify patients with late-onset Alzheimer compared with age-matched controls. Methods: A case-control study was performed. Blood DNA methylation levels at 46 cytosine-guanine sites (21 genes selected after a comprehensive literature search) were measured by bisulfite pyrosequencing in patients with “probable AD dementia” following National Institute on Aging and the Alzheimer's Association guidelines (2011) and age-matched and sex-matched controls recruited at Neurology Department-University Hospital of Navarre, Spain, selected by convenience sampling. Plasma pTau181 levels were determined by Simoa technology. Multivariable logistic regression analysis was performed to explore the optimal model to discriminate patients with AD from controls. Furthermore, we performed a stratified analysis by sex. Results: The final study cohort consisted of 80 patients with AD (age: median [interquartile range] 79 [11] years; 58.8% female) and 100 cognitively healthy controls (age 77 [10] years; 58% female). A panel including DNA methylation levels at NXN, ABCA7, and HOXA3 genes and plasma pTau181 significantly improved (area under the receiver operating characteristic curve 0.93, 95% CI 0.89–0.97) the diagnostic performance of a single pTau181-based model, adjusted for age, sex, and APOE ɛ4 genotype. The sensitivity and specificity of this panel were 83.30% and 90.00%, respectively. After sex-stratified analysis, HOXA3 DNA methylation levels showed consistent association with AD. Discussion: These results highlight the potential translational value of blood-based DNA methylation biomarkers for noninvasive diagnosis of AD. Registration Information: Research Ethics Committee of the University Hospital of Navarre (PI17/02218)., Spanish Government through grants from the Institute of Health Carlos III (FIS PI17/02218), jointly funded by the European Regional Development Fund (ERDF), European Union, A way of shaping Europe; the Department of Industry of Government of Navarra (PI058 iBEAS-Plus and PI055 iBEAS-Plus); Institute of Health Carlos III (FIS PI20/01330 and AC19/00103 to AL) and CIBERNED (Program 1, Alzheimer Disease). The project leading to these results has received funding from la Caixa Foundation (ID 100010434) co-funded by Fundación Luzón (HR20-01109_BIOP-AD) under the project code LCF/PR/PR15/51100006.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publication Artículo científico (JournalArticle)

Unravelling the Inflammatory Processes in the Early Stages of Diabetic Nephropathy and the Potential Effect of (S-s)-DS-ONJ

  • Gómez Jaramillo, María Laura
  • Cano-Cano, Fátima
  • Sánchez-Fernández, Elena M.
  • Ortiz Mellet, Carmen
  • García-Fernández, José M.
  • Alcalá, Martin
  • Álvarez-Gallego, Fabiola
  • Iturregui, Marta
  • González Montelongo, María del Carmen
  • Campos Caro, Antonio
  • Arroba Espinosa, Ana Isabel
  • Aguilar Diosdado, Manuel
Inflammatory processes play a central role in the pathogenesis of diabetic nephropathy (DN) in the early stages of the disease. The authors demonstrate that the glycolipid mimetic (Ss)-DS-ONJ is able to abolish inflammation via the induction of autophagy flux and provokes the inhibition of inflammasome complex in ex vivo and in vitro models, using adult kidney explants from BB rats. The contribution of (Ss)-DS-ONJ to reducing inflammatory events is mediated by the inhibition of classical stress kinase pathways and the blocking of inflammasome complex activation. The (Ss)-DS-ONJ treatment is able to inhibit the epithelial-to-mesenchymal transition (EMT) progression, but only when the IL18 levels are reduced by the treatment. These findings suggest that (Ss)-DS-ONJ could be a novel, and multifactorial treatment for DN.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Basal forebrain atrophy along the Alzheimer's disease continuum in adults with Down syndrome

  • Aranha, Mateus Rozalem
  • Iulita, Maria Florencia
  • Montal, Victor
  • Pegueroles, Jordi
  • Bejanin, Alexandre
  • Vaqué-Alcázar, Lídia
  • Grothe, Michel J.
  • Carmona-Iragui, Maria
  • Videla, Laura
  • Benejam, Bessy
  • Arranz, Javier
  • Padilla, Concepción
  • Valldeneu, Sílvia
  • Barroeta, Isabel
  • Altuna, Miren
  • Fernández, Susana
  • Ribas, Laia
  • Valle-Tamayo, Natalia
  • Alcolea, Daniel
  • González-Ortiz, Sofía
  • Bargalló, Núria
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Blesa, Rafael
  • Wisniewski, Thomas
  • Busciglio, Jorge
  • Cuello, A. Claudio
  • Lleó, Alberto
  • Fortea, Juan
[Background] Basal forebrain (BF) degeneration occurs in Down syndrome (DS)-associated Alzheimer's disease (AD). However, the dynamics of BF atrophy with age and disease progression, its impact on cognition, and its relationship with AD biomarkers have not been studied in DS., [Methods] We included 234 adults with DS (150 asymptomatic, 38 prodromal AD, and 46 AD dementia) and 147 euploid controls. BF volumes were extracted from T-weighted magnetic resonance images using a stereotactic atlas in SPM12. We assessed BF volume changes with age and along the clinical AD continuum and their relationship to cognitive performance, cerebrospinal fluid (CSF) and plasma amyloid/tau/neurodegeneration biomarkers, and hippocampal volume., [Results] In DS, BF volumes decreased with age and along the clinical AD continuum and significantly correlated with amyloid, tau, and neurofilament light chain changes in CSF and plasma, hippocampal volume, and cognitive performance., [Discussion] BF atrophy is a potentially valuable neuroimaging biomarker of AD-related cholinergic neurodegeneration in DS., This study was supported by the Fondo de Investigaciones Sanitario, Carlos III Health Institute (PI20/01473 to JF, PI13/01532, PI16/01825 to RB, PI18/00335 to MCI, PI18/00435 to DA, PI14/1561, PI20/01330 to AL, PI20/00613 to MJG) and the CIBERNED Program 1. This work was also supported by the National Institutes of Health (NIH) grants (1R01AG056850-01A1; 3RF1AG056850-01S1; AG056850, R21AG056974, and R01AG061566 to JF; P30AG066512 and P01AG060882 to TW), Departament de Salut de la Generalitat de Catalunya, Fundación Tatiana Pérez de Guzmán el Bueno (IIBSP-DOW-2020-151 to JF), and the European Union's Horizon 2020, ‘MES-CoBraD’ (H2020-SC1-BHC-2018-2020 / GA 965422 to JF). MRA acknowledges support from the Alzheimer's Association Research Fellowship to Promote Diversity (AARF-D) Program (AARFD-21-852492). MFI acknowledges support from the Jérôme Lejeune postdoctoral award and pilot grant (#1941). AB acknowledges support from a Miguel Servet grant (CP20/00038) from the Carlos III Health Institute. MJG acknowledges support from a Miguel Servet grant (CP19/00031) from the Carlos III Health Institute. MCI acknowledges support from the Alzheimer's Association and Global Brain Health Institute (GBHI_ALZ-18-543740), the Jérôme Lejeune Foundation (#1913 Cycle 2019B), and the Societat Catalana de Neurologia (Premi Beca Fundació SCN 2020). LVA was supported by Margarita Salas junior postdoctoral fellowship (UNI/551/2021, NextGenerationUE). VM and NVT acknowledge support from predoctoral grants from the Carlos III Health Institute (FI18/00275 to VM and FI22/00077 to NVT). MA and JA were supported by the Río Hortega Fellowship from Carlos III Health Institute (CM19/00066 to MA and CM21/00243 to JA). CP acknowledges support from a Sara Borrell Fellowship (CP20/00133) from the Carlos III Health Institute. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712 and #101053962), Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (#2017-00915), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721 and #AF-968270), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), and the Alzheimer's Association 2021 Zenith Award (ZEN-21-848495)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration

  • Cervantes González, Alba|||0000-0003-1006-6719
  • Irwin, David J.|||0000-0002-5599-5098
  • Alcolea, Daniel|||0000-0002-3819-3245
  • McMillan, Corey T.|||0000-0002-7581-6405
  • Chen-Plotkin, Alice
  • Wolk, David
  • Sirisi Dolcet, Sonia|||0000-0002-5366-7832
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Querol-Vilaseca, Marta|||0000-0002-8589-1636
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Fortea, Juan|||0000-0002-1340-638X
  • Lee, Edward B.
  • Trojanowski, John Q.|||0000-0002-9239-8794
  • Grossman, Murray|||0000-0002-7447-6218
  • Lleó, Alberto|||0000-0002-2568-5478
  • Belbin, Olivia|||0000-0002-6109-6371
Synapse degeneration is an early event in pathological frontotemporal lobar degeneration (FTLD). Consequently, a surrogate marker of synapse loss could be used to monitor early pathologic changes in patients with underlying FTLD. The aim of this study was to evaluate the relationship of antemortem cerebrospinal fluid (CSF) levels of 8 synaptic proteins with postmortem global tau and TDP-43 burden and cognitive performance and to assess their diagnostic capacity in a neuropathological FTLD cohort. We included patients with a neuropathological confirmation of FTLD-Tau (n = 24, mean age-at-CSF 67 years ± 11), FTLD-TDP (n = 25, 66 years ± 9) or AD (n = 25, 73 years ± 6) as well as cognitively normal controls (n = 35, 69 years ± 7) from the Penn FTD Center and ADRC. We used a semi-quantitative measure of tau and TDP-43 inclusions to quantify pathological burden across 16 brain regions. Statistical methods included Spearman rank correlations, one-way analysis of covariance, ordinal regression, step-wise multiple linear regression and receiver-operating characteristic curves. CSF calsyntenin-1 and neurexin-2a were correlated in all patient groups (r = .55 to.88). In FTLD-TDP, we observed low antemortem CSF levels of calsyntenin-1 and neurexin-2a compared to AD (.72-fold, p = .001,.77-fold, p = .04, respectively) and controls (.80-fold, p = .02,.78-fold, p = .02, respectively), which were inversely associated with post-mortem global TDP-43 burden (regression r 2 = .56, p = .007 and r 2 = .57, p = .006, respectively). A multimarker panel including calsyntenin-1 was associated with TDP-43 burden (r 2 = .69, p = .003) and MMSE score (r 2 = .19, p = .03) in FTLD. A second multimarker synaptic panel, also including calsyntenin-1, was associated with MMSE score in FTLD-tau (r 2 = .49, p = .04) and improved diagnostic performance to discriminate FTLD-Tau and FTLD-TDP neuropathologic subtypes (AUC = .83). These synaptic panels have potential in the differential diagnosis of FTLD neuropathologic subtypes and as surrogate markers of cognitive performance in future clinical trials targeting TDP-43 or tau. The online version contains supplementary material available at 10.1186/s13024-022-00534-y.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Association of biological sex with clinical outcomes and biomarkers of Alzheimer's disease in adults with Down syndrome

  • Iulita, M. Florencia|||0000-0002-3360-4498
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Benejam, Bessy|||0000-0002-6789-8615
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Fernández, Susana|||0000-0002-9777-1156
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Montal, Victor|||0000-0002-5714-9282
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Giménez, Sandra|||0000-0001-8031-2319
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Torres Alcalá, Soraya|||0000-0002-7054-2046
  • El Bounasri El Bennadi, Shaimaa|||0000-0003-1580-9649
  • Padilla, Concepción|||0000-0003-4102-6787
  • Aranha, Mateus|||0000-0001-9594-292X
  • Estellés, Teresa
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Belbin, Olivia|||0000-0002-6109-6371
  • Valle-Tamayo, Natalia|||0000-0001-9322-3710
  • Camacho, Valle|||0000-0003-0748-0847
  • Blessing, Esther
  • Osorio, Ricardo S.
  • Videla, Sebastián|||0000-0001-5049-1379
  • Lehmann, Sylvain|||0000-0001-6117-562X
  • Holland, Anthony J.
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Blennow, Kaj|||0000-0002-1890-4193
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Zaman, Shahid
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
The study of sex differences in Alzheimer's disease is increasingly recognized as a key priority in research and clinical development. People with Down syndrome represent the largest population with a genetic link to Alzheimer's disease (.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration

  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Nigro, Salvatore
  • Vandevrede, Lawren
  • Falgàs, Neus|||0000-0002-3404-2765
  • Heuer, Hilary W.
  • Painous, Cèlia|||0000-0002-7027-3093
  • Compta, Yaroslau|||0000-0001-6443-0104
  • Martí Domenech, Maria Josep|||0000-0002-9872-7835
  • Montal, Victor|||0000-0002-5714-9282
  • Pagonabarraga Mora, Javier|||0000-0002-3248-704X
  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Logroscino, Giancarlo|||0000-0003-0423-3242
  • Quattrone, Andrea
  • Perry, David C.
  • Gorno-Tempini, Maria Luisa
  • Rosen, Howard J.|||0000-0001-9281-7402
  • Grinberg, Lea T.
  • Spina, Salvatore
  • La Joie, Renaud
  • Rabinovici, Gil D.
  • Miller, Bruce L.|||0000-0002-2152-4220
  • Rojas, Julio C.|||0000-0002-1308-646X
  • Seeley, William W.
  • Boxer, Adam
Importance: The accurate diagnosis of progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) is hampered by imperfect clinical-pathological correlations. Objective: To assess and compare the diagnostic value of the magnetic resonance parkinsonism index (MRPI) and other magnetic resonance imaging-based measures of cerebral atrophy to differentiate between PSP, CBD, and other neurodegenerative diseases. Design, Setting, and Participants: This prospective diagnostic study included participants with 4-repeat tauopathies (4RT), PSP, CBD, other neurodegenerative diseases and available MRI who appeared in the University of California, San Francisco, Memory and Aging Center database. Data were collected from October 27, 1994, to September 29, 2019. Data were analyzed from March 1 to September 14, 2021. Main Outcomes and Measures: The main outcome of this study was the neuropathological diagnosis of PSP or CBD. The clinical diagnosis at the time of the MRI acquisition was noted. The imaging measures included the MRPI, cortical thickness, subcortical volumes, including the midbrain, pons, and superior cerebellar peduncle volumes. Multinomial logistic regression models (MLRM) combining different cortical and subcortical regions were defined to discriminate between PSP, CBD, and other pathologies. The areas under the receiver operating characteristic curves (AUROC) and cutoffs were calculated to differentiate between PSP, CBD, and other diseases. Results: Of the 326 included participants, 176 (54%) were male, and the mean (SD) age at MRI was 64.1 (8.0) years. The MRPI showed good diagnostic accuracy for the differentiation between PSP and all other pathologies (accuracy, 87%; AUROC, 0.90; 95% CI, 0.86-0.95) and between 4RT and other pathologies (accuracy, 80%; AUROC, 0.82; 95% CI, 0.76-0.87), but did not allow the discrimination of participants with CBD. Its diagnostic accuracy was lower in the subgroup of patients without the canonical PSP-Richardson syndrome (PSP-RS) or probable corticobasal syndrome (CBS) at MRI. MLRM combining cortical and subcortical measurements showed the highest accuracy for the differentiation between PSP and other pathologies (accuracy, 95%; AUROC, 0.98; 95% CI, 0.97-0.99), CBD and other pathologies (accuracy, 83%; AUROC, 0.86; 95% CI, 0.81-0.91), 4RT and other pathologies (accuracy, 89%; AUROC, 0.94; 95% CI, 0.92-0.97), and PSP and CBD (accuracy, 91%; AUROC, 0.95; 95% CI, 0.91-0.99), even in participants without PSP-RS or CBS at MRI. Conclusions and Relevance: In this study, the combination of widely available cortical and subcortical measures of atrophy on MRI discriminated between PSP, CBD, and other pathologies and could be used to support the diagnosis of 4RT in clinical practice.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cortical microstructure in primary progressive aphasia, a multicenter study

  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Montal, Victor|||0000-0002-5714-9282
  • Borrego-Écija, Sergi|||0000-0003-2557-0010
  • Mandelli, Maria Luisa|||0000-0002-2518-2520
  • Falgàs, Neus|||0000-0002-3404-2765
  • Welch, Ariane E.
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Belbin, Olivia|||0000-0002-6109-6371
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Bargalló, Núria|||0000-0001-6284-5402
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Blesa, Rafael|||0000-0003-4026-2884
  • Dickerson, Bradford C.
  • Rosen, Howard J.|||0000-0001-9281-7402
  • Miller, Bruce L.|||0000-0002-2152-4220
  • Lleó, Alberto|||0000-0002-2568-5478
  • Gorno-Tempini, Maria Luisa
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Fortea, Juan|||0000-0002-1340-638X
Background: Cortical mean diffusivity is a novel imaging metric sensitive to early changes in neurodegenerative syndromes. Higher cortical mean diffusivity values reflect microstructural disorganization and have been proposed as a sensitive biomarker that might antedate macroscopic cortical changes. We aimed to test the hypothesis that cortical mean diffusivity is more sensitive than cortical thickness to detect cortical changes in primary progressive aphasia (PPA). Methods: In this multicenter, case-control study, we recruited 120 patients with PPA (52 non-fluent, 31 semantic, and 32 logopenic variants; and 5 GRN-related PPA) as well as 89 controls from three centers. The 3-Tesla MRI protocol included structural and diffusion-weighted sequences. Disease severity was assessed with the Clinical Dementia Rating scale. Cortical thickness and cortical mean diffusivity were computed using a surface-based approach. Results: The comparison between each PPA variant and controls revealed cortical mean diffusivity increases and cortical thinning in overlapping regions, reflecting the canonical loci of neurodegeneration of each variant. Importantly, cortical mean diffusivity increases also expanded to other PPA-related areas and correlated with disease severity in all PPA groups. Cortical mean diffusivity was also increased in patients with very mild PPA when only minimal cortical thinning was observed and showed a good correlation with measures of disease severity. Conclusions: Cortical mean diffusivity shows promise as a sensitive biomarker for the study of the neurodegeneration-related microstructural changes in PPA.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Characteristics of subjective cognitive decline associated with amyloid positivity

  • Janssen, Olin|||0000-0002-8341-0958
  • Jansen, Willemijn J.
  • Vos, Stephanie J.B.|||0000-0002-2045-9818
  • Boada, Mercè|||0000-0003-2617-3009
  • Parnetti, Lucilla|||0000-0001-5722-3967
  • Gabryelewicz, Tomasz
  • Fladby, Tormod|||0000-0002-9984-9797
  • Molinuevo, José Luis|||0000-0003-0485-6001
  • Villeneuve, Sylvia
  • Hort, Jakub|||0000-0002-1080-3726
  • Epelbaum, Stéphane
  • Lleó, Alberto|||0000-0002-2568-5478
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • Landau, Susan
  • Popp, Julius|||0000-0002-0068-0312
  • Wallin, Anders|||0000-0001-9506-0513
  • Scheltens, Philip|||0000-0002-1046-6408
  • Rikkert, Marcel Olde|||0000-0003-1397-1677
  • Snyder, Peter J.|||0000-0003-0555-4654
  • Rowe, Chris
  • Chételat, G.|||0000-0002-4889-7932
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Marquié, Marta|||0000-0002-0660-0950
  • Chipi, Elena
  • Wolfsgruber, Steffen
  • Heneka, Michael|||0000-0003-4996-1630
  • Boecker, Henning|||0000-0003-2346-0598
  • Peters, Oliver|||0000-0003-0568-2998
  • Jarholm, Jonas
  • Rami Gonzalez, Lorena|||0000-0002-7411-1921
  • Tort-Merino, Adrià|||0000-0002-5646-0482
  • Pichet Binette, Alexa|||0000-0001-5218-3337
  • Poirier, Judes
  • Rosa-Neto, Pedro|||0000-0001-9116-1376
  • Cerman, Jiri
  • Dubois, Bruno
  • Teichmann, Marc
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Ebenau, Jarith
  • Pocnet, Cornelia
  • Eckerström, Marie
  • Thompson, Louisa
  • Villemagne, Victor
  • Buckley, Rachel|||0000-0002-5356-5537
  • Burnham, Samantha
  • Delarue, Marion
  • Freund-Levi, Yvonne|||0000-0001-6863-6679
  • Wallin, Åsa K.
  • Ramakers, Inez
  • Tsolaki, Magda|||0000-0002-2072-8010
  • Soininen, Hilkka|||0000-0002-2785-9937
  • Hampel, Harald
  • Spiru, Luiza
  • Tijms, Betty M.|||0000-0002-2612-1797
  • Ossenkoppele, Rik
  • Verhey, Frans
  • Jessen, Frank
  • Visser, Pieter Jelle|||0000-0001-8008-9727
Introduction: The evidence for characteristics of persons with subjective cognitive decline (SCD) associated with amyloid positivity is limited. Methods: In 1640 persons with SCD from 20 Amyloid Biomarker Study cohort, we investigated the associations of SCD-specific characteristics (informant confirmation, domain-specific complaints, concerns, feelings of worse performance) demographics, setting, apolipoprotein E gene (APOE) ε4 carriership, and neuropsychiatric symptoms with amyloid positivity. Results: Between cohorts, amyloid positivity in 70-year-olds varied from 10% to 76%. Only older age, clinical setting, and APOE ε4 carriership showed univariate associations with increased amyloid positivity. After adjusting for these, lower education was also associated with increased amyloid positivity. Only within a research setting, informant-confirmed complaints, memory complaints, attention/concentration complaints, and no depressive symptoms were associated with increased amyloid positivity. Feelings of worse performance were associated with less amyloid positivity at younger ages and more at older ages. Discussion: Next to age, setting, and APOE ε4 carriership, SCD-specific characteristics may facilitate the identification of amyloid-positive individuals.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Basal forebrain atrophy along the Alzheimer's disease continuum in adults with Down syndrome

  • Aranha, Mateus|||0000-0001-9594-292X
  • Iulita, M. Florencia|||0000-0002-3360-4498
  • Montal, Victor|||0000-0002-5714-9282
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Grothe, Michel|||0000-0003-2600-9022
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Benejam, Bessy|||0000-0002-6789-8615
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Padilla, Concepción|||0000-0003-4102-6787
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Fernández, Susana|||0000-0002-9777-1156
  • Ribas, Laia
  • Valle-Tamayo, Natalia|||0000-0001-9322-3710
  • Alcolea, Daniel|||0000-0002-3819-3245
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Bargalló, Núria|||0000-0001-6284-5402
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Blennow, Kaj|||0000-0002-1890-4193
  • Blesa, Rafael|||0000-0003-4026-2884
  • Wisniewski, Thomas M.
  • Busciglio, Jorge A.
  • Cuello, AC.|||0000-0003-2143-2745
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
Background: Basal forebrain (BF) degeneration occurs in Down syndrome (DS)-associated Alzheimer's disease (AD). However, the dynamics of BF atrophy with age and disease progression, its impact on cognition, and its relationship with AD biomarkers have not been studied in DS. Methods: We included 234 adults with DS (150 asymptomatic, 38 prodromal AD, and 46 AD dementia) and 147 euploid controls. BF volumes were extracted from T-weighted magnetic resonance images using a stereotactic atlas in SPM12. We assessed BF volume changes with age and along the clinical AD continuum and their relationship to cognitive performance, cerebrospinal fluid (CSF) and plasma amyloid/tau/neurodegeneration biomarkers, and hippocampal volume. Results: In DS, BF volumes decreased with age and along the clinical AD continuum and significantly correlated with amyloid, tau, and neurofilament light chain changes in CSF and plasma, hippocampal volume, and cognitive performance. Discussion: BF atrophy is a potentially valuable neuroimaging biomarker of AD-related cholinergic neurodegeneration in DS.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer's disease

  • Campo Milán, Marta del|||0000-0003-2808-3699
  • Vermunt, Lisa
  • Peeters, Carel F.W.
  • Sieben, Anne|||0000-0003-1278-6605
  • Hok-A-Hin, Yanaika S.|||0000-0001-9713-116X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
  • van Nee, Mirrelijn
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • van Alphen, Juliette L.
  • Arezoumandan, Sanaz
  • Chen-Plotkin, Alice
  • Irwin, David J.|||0000-0002-5599-5098
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • Lemstra, Afina W.|||0000-0002-8933-3260
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
Diagnosis of dementia with Lewy bodies (DLB) is challenging and specific biofluid biomarkers are highly needed. We employed proximity extension-based assays to measure 665 proteins in the cerebrospinal fluid (CSF) from patients with DLB (n = 109), Alzheimer's disease (AD, n = 235) and cognitively unimpaired controls (n = 190). We identified over 50 CSF proteins dysregulated in DLB, enriched in myelination processes among others. The dopamine biosynthesis enzyme DDC was the strongest dysregulated protein, and could efficiently discriminate DLB from controls and AD (AUC:0.91 and 0.81 respectively). Classification modeling unveiled a 7-CSF biomarker panel that better discriminate DLB from AD (AUC:0.93). A custom multiplex panel for six of these markers (DDC, CRH, MMP-3, ABL1, MMP-10, THOP1) was developed and validated in independent cohorts, including an AD and DLB autopsy cohort. This DLB CSF proteome study identifies DLB-specific protein changes and translates these findings to a practicable biomarker panel that accurately identifies DLB patients, providing promising diagnostic and clinical trial testing opportunities.